A young person with Duchenne muscular dystrophy died ... gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta ...

Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

Verve Therapeutics said Monday that initial data show that its investigational gene-editing therapy lowered cholesterol ...

after acknowledging the sudden death of a patient with Duchenne muscular dystrophy (DMD) following treatment with the company’s marketed gene therapy. The patient, whom Sarepta described as a ...

In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy ... especially after the recent patient death due to ...

(Reuters) - Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.

A new paper published in Gene Therapy raises serious concerns about the effectiveness of gene therapy for Duchenne muscular ...